156 related articles for article (PubMed ID: 15837297)
1. 3-Acyl-2,6-diaminopyridines as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
Lin R; Lu Y; Wetter SK; Connolly PJ; Turchi IJ; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Adams M; Pandey N; Moreno-Mazza S; Middleton SA; Jolliffe LK
Bioorg Med Chem Lett; 2005 May; 15(9):2221-4. PubMed ID: 15837297
[TBL] [Abstract][Full Text] [Related]
2. 1-Acyl-1H-[1,2,4]triazole-3,5-diamine analogues as novel and potent anticancer cyclin-dependent kinase inhibitors: synthesis and evaluation of biological activities.
Lin R; Connolly PJ; Huang S; Wetter SK; Lu Y; Murray WV; Emanuel SL; Gruninger RH; Fuentes-Pesquera AR; Rugg CA; Middleton SA; Jolliffe LK
J Med Chem; 2005 Jun; 48(13):4208-11. PubMed ID: 15974571
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors.
Lee J; Choi H; Kim KH; Jeong S; Park JW; Baek CS; Lee SH
Bioorg Med Chem Lett; 2008 Apr; 18(7):2292-5. PubMed ID: 18353638
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and identification of [1,3,5]triazine-pyridine biheteroaryl as a novel series of potent cyclin-dependent kinase inhibitors.
Kuo GH; Deangelis A; Emanuel S; Wang A; Zhang Y; Connolly PJ; Chen X; Gruninger RH; Rugg C; Fuentes-Pesquera A; Middleton SA; Jolliffe L; Murray WV
J Med Chem; 2005 Jul; 48(14):4535-46. PubMed ID: 15999992
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors.
Lin R; Chiu G; Yu Y; Connolly PJ; Li S; Lu Y; Adams M; Fuentes-Pesquera AR; Emanuel SL; Greenberger LM
Bioorg Med Chem Lett; 2007 Aug; 17(16):4557-61. PubMed ID: 17574416
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and biological activity of N-aryl-2-aminothiazoles: potent pan inhibitors of cyclin-dependent kinases.
Misra RN; Xiao HY; Williams DK; Kim KS; Lu S; Keller KA; Mulheron JG; Batorsky R; Tokarski JS; Sack JS; Kimball SD; Lee FY; Webster KR
Bioorg Med Chem Lett; 2004 Jun; 14(11):2973-7. PubMed ID: 15125971
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors.
Chang YT; Gray NS; Rosania GR; Sutherlin DP; Kwon S; Norman TC; Sarohia R; Leost M; Meijer L; Schultz PG
Chem Biol; 1999 Jun; 6(6):361-75. PubMed ID: 10375538
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological activity of 2-anilino-4-(1H-pyrrol-3-yl) pyrimidine CDK inhibitors.
Wang S; Wood G; Meades C; Griffiths G; Midgley C; McNae I; McInnes C; Anderson S; Jackson W; Mezna M; Yuill R; Walkinshaw M; Fischer PM
Bioorg Med Chem Lett; 2004 Aug; 14(16):4237-40. PubMed ID: 15261277
[TBL] [Abstract][Full Text] [Related]
9. 4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects.
Krystof V; Cankar P; Frysová I; Slouka J; Kontopidis G; Dzubák P; Hajdúch M; Srovnal J; de Azevedo WF; Orság M; Paprskárová M; Rolcík J; Látr A; Fischer PM; Strnad M
J Med Chem; 2006 Nov; 49(22):6500-9. PubMed ID: 17064068
[TBL] [Abstract][Full Text] [Related]
10. Imidazole piperazines: SAR and development of a potent class of cyclin-dependent kinase inhibitors with a novel binding mode.
Finlay MR; Acton DG; Andrews DM; Barker AJ; Dennis M; Fisher E; Graham MA; Green CP; Heaton DW; Karoutchi G; Loddick SA; Morgentin R; Roberts A; Tucker JA; Weir HM
Bioorg Med Chem Lett; 2008 Aug; 18(15):4442-6. PubMed ID: 18617397
[TBL] [Abstract][Full Text] [Related]
11. Specific inhibition of cyclin-dependent kinases and cell proliferation by harmine.
Song Y; Kesuma D; Wang J; Deng Y; Duan J; Wang JH; Qi RZ
Biochem Biophys Res Commun; 2004 Apr; 317(1):128-32. PubMed ID: 15047157
[TBL] [Abstract][Full Text] [Related]
12. Aloisines, a new family of CDK/GSK-3 inhibitors. SAR study, crystal structure in complex with CDK2, enzyme selectivity, and cellular effects.
Mettey Y; Gompel M; Thomas V; Garnier M; Leost M; Ceballos-Picot I; Noble M; Endicott J; Vierfond JM; Meijer L
J Med Chem; 2003 Jan; 46(2):222-36. PubMed ID: 12519061
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and evaluation of 2-methyl- and 2-amino-N-aryl-4,5-dihydrothiazolo[4,5-h]quinazolin-8-amines as ring-constrained 2-anilino-4-(thiazol-5-yl)pyrimidine cyclin-dependent kinase inhibitors.
McIntyre NA; McInnes C; Griffiths G; Barnett AL; Kontopidis G; Slawin AM; Jackson W; Thomas M; Zheleva DI; Wang S; Blake DG; Westwood NJ; Fischer PM
J Med Chem; 2010 Mar; 53(5):2136-45. PubMed ID: 20146435
[TBL] [Abstract][Full Text] [Related]
14. Design, synthesis, and biological evaluation of novel pyrimidine derivatives as CDK2 inhibitors.
Ibrahim DA; El-Metwally AM
Eur J Med Chem; 2010 Mar; 45(3):1158-66. PubMed ID: 20045222
[TBL] [Abstract][Full Text] [Related]
15. 3-Hydroxychromones as cyclin-dependent kinase inhibitors: synthesis and biological evaluation.
Lee J; Park T; Jeong S; Kim KH; Hong C
Bioorg Med Chem Lett; 2007 Mar; 17(5):1284-7. PubMed ID: 17178224
[TBL] [Abstract][Full Text] [Related]
16. Structure-based design of a new class of highly selective aminoimidazo[1,2-a]pyridine-based inhibitors of cyclin dependent kinases.
Hamdouchi C; Zhong B; Mendoza J; Collins E; Jaramillo C; De Diego JE; Robertson D; Spencer CD; Anderson BD; Watkins SA; Zhang F; Brooks HB
Bioorg Med Chem Lett; 2005 Apr; 15(7):1943-7. PubMed ID: 15780638
[TBL] [Abstract][Full Text] [Related]
17. Novel naphthoquinone and quinolinedione inhibitors of CDC25 phosphatase activity with antiproliferative properties.
Braud E; Goddard ML; Kolb S; Brun MP; Mondésert O; Quaranta M; Gresh N; Ducommun B; Garbay C
Bioorg Med Chem; 2008 Oct; 16(19):9040-9. PubMed ID: 18789703
[TBL] [Abstract][Full Text] [Related]
18. Recent advances and new directions in the discovery and development of cyclin-dependent kinase inhibitors.
Fischer PM
Curr Opin Drug Discov Devel; 2001 Sep; 4(5):623-34. PubMed ID: 12825457
[TBL] [Abstract][Full Text] [Related]
19. Aminoimidazo[1,2-a]pyridines as a new structural class of cyclin-dependent kinase inhibitors. Part 1: Design, synthesis, and biological evaluation.
Jaramillo C; de Diego JE; Hamdouchi C; Collins E; Keyser H; Sánchez-Martínez C; del Prado M; Norman B; Brooks HB; Watkins SA; Spencer CD; Dempsey JA; Anderson BD; Campbell RM; Leggett T; Patel B; Schultz RM; Espinosa J; Vieth M; Zhang F; Timm DE
Bioorg Med Chem Lett; 2004 Dec; 14(24):6095-9. PubMed ID: 15546737
[TBL] [Abstract][Full Text] [Related]
20. Variolin B and its derivate deoxy-variolin B: new marine natural compounds with cyclin-dependent kinase inhibitor activity.
Simone M; Erba E; Damia G; Vikhanskaya F; Di Francesco AM; Riccardi R; Bailly C; Cuevas C; Fernandez Sousa-Faro JM; D'Incalci M
Eur J Cancer; 2005 Oct; 41(15):2366-77. PubMed ID: 16181779
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
